newsfilter
← Latest News
Business Wire·

NeoGenomics to Present New ctDNA Research at SABCS 2025

Data include findings generated using the RaDaR 1.0 assay to assess molecular residual disease and recurrence risk in early breast cancer NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic